Supernus Pharmaceuticals, Inc.
Rank #104StartupSUPN · Nasdaq · Healthcare
Supernus Pharmaceuticals, Inc. (SUPN) — Rank #104 by gross profitability (GP/assets 0.45) · ROE -3.7% · Piotroski F-Score N/A.
As-of 2026-09-28 · CIK 0001356576 · all metrics point-in-time as of the filing date.
About
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Show moreShow less
It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc.
was incorporated in 2005 and is based in Rockville, Maryland.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- supernus.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-02 | 2024-12-31filed 2025-02-25 | 2023-12-31filed 2025-02-25 | 2022-12-31filed 2023-03-09 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 91.6 | 80.4 | 84.9 | 85.5 |
| Stock-based compensation | 33.1 | 27.8 | 26.8 | 17.6 |
| Change in receivables | 22.3 | (2.1) | (18.8) | 16.4 |
| Change in inventory | 7.5 | (15.8) | (6.1) | 17.9 |
| Change in payables | — | — | — | — |
| Operating cash flow | 47.3 | 172.0 | 111.1 | 116.8 |
| Investing | ||||
| Capital expenditures | 1.3 | 0.7 | — | — |
| Acquisitions, net of cash | 293.1 | — | — | 0.0 |
| Investing cash flow | 4.1 | (189.9) | 268.7 | (216.7) |
| Financing | ||||
| Financing cash flow | 9.1 | 12.2 | (397.9) | (10.5) |
| Summary | ||||
| Free cash flow | 46.0 | 171.2 | 171.2 | — |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?